Results 141 to 150 of about 1,440 (183)

Imaging findings for 2-[¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in blastic plasmacytoid dendritic cell neoplasm: case series and literature review. [PDF]

Front Med (Lausanne)
Zhou Y, Li K, Jin X, Yuan L, Zhou H, Li X.   +5 more
europepmc   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. [PDF]

Iran J Pathol
Nayeri F, Nematolahi P, Mohamadi B.
europepmc   +1 more source

Proliferation of CD10⁺ mature plasmacytoid dendritic cells in lymph nodes of patients with chronic non-tuberculous mycobacterial infection: a case report. [PDF]

J Med Case Rep
Zhang L, Jiang J, Chen X, Sun Y, Lu Y.
europepmc   +1 more source

Single cell sequencing deciphering the heterogeneous landscape of blastic plasmacytoid dendritic cell neoplasm with novel MYB-ZFAT fusion gene. [PDF]

Cancer Cell Int
Li R, Kuang W, Yang H, Zhang B, Zhao K, Fang W, Cheng Z, Fu X, Peng H.   +8 more
europepmc   +1 more source

Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?

Cancers, 2022
No benchmark treatment exists for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Since the malignancy is chemo-sensitive, chemotherapy followed by hematopoietic stem cell transplantation remains an effective treatment. However, relapses frequently occur with the development of resistance.
Eric Deconinck, Fanny Angelot-Delettre
exaly   +4 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

Current Hematologic Malignancy Reports, 2018
Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient ...
Andrew Lane, Vikas Gupta, Naveen Pemmaraju   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Targeting CD123 in BPDCN: an emerging field

Expert Review of Hematology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on targeted therapy to improve responses and limit potential toxicity.CD123 (also known as IL-3 Rα) is a cell surface marker and ...
Naveen Pemmaraju, Adam Dipippo, Nathaniel Wilson   +2 more
exaly   +3 more sources

Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations [PDF]

Annals of Hematology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy derived from plasmacytoid dendritic cells, can mimic both acute leukemia and aggressive T-cell lymphoma.
Ulrike Bacher, Paolo Mazzeo, Soren Alexander Weidemann   +2 more
exaly   +5 more sources

Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN): Clinical Features and Histopathology with a Therapeutic Overview

Hematology Reports, 2023
Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCNs) are a rare, highly aggressive hematological malignant neoplasm that primarily involve the skin, bone marrow, lymph nodes and even extra-nodal sites.
Giuseppe Ingravallo, Francesco Gaudio, Gerardo Cazzato   +2 more
exaly   +2 more sources